File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Conference Paper: Measuring the molecular force of Burkitt's lymphoma patient cells using AFM

TitleMeasuring the molecular force of Burkitt's lymphoma patient cells using AFM
Authors
Issue Date2010
Citation
2010 IEEE International Conference on Nano/Molecular Medicine and Engineering, IEEE NANOMED 2010, 2010, p. 176-179 How to Cite?
AbstractThe treatment of Non-Hodgkin's lymphoma (NHL) was revolutionized by the approval of rituximab in 1997. Rituximab is a CD20-directed monoclonal antibody (mAb). Despite the great success of rituximab in the treatment of B-cell NHL, the urgent need is to enhance the efficacy due to the markedly variable patient responses. Hence elucidating the molecular mechanisms of rituximab's anti-cancer effect is of great significance. In the past decade the atomic force microscopy (AFM) has proven to be a powerful tool for characterizing the morphological properties and measuring the physiological interaction forces of single cells and single molecules under native conditions. In this work, the AFM single-molecule force spectroscopy(SMFS) was applied to quantitatively measure the CD20-rituximab binding force on Burkitt's lymphoma patient bone marrow cells. The experimental results will facilitate further investigation of the molecular mechanisms of rituximab's anticancer effect. © 2010 IEEE.
Persistent Identifierhttp://hdl.handle.net/10722/213173

 

DC FieldValueLanguage
dc.contributor.authorLi, Mi-
dc.contributor.authorLiu, Lianqing-
dc.contributor.authorXi, Ning-
dc.contributor.authorWang, Yuechao-
dc.contributor.authorDong, Zaili-
dc.contributor.authorLi, Guangyong-
dc.contributor.authorXiao, Xiubin-
dc.contributor.authorZhang, Weijing-
dc.date.accessioned2015-07-28T04:06:23Z-
dc.date.available2015-07-28T04:06:23Z-
dc.date.issued2010-
dc.identifier.citation2010 IEEE International Conference on Nano/Molecular Medicine and Engineering, IEEE NANOMED 2010, 2010, p. 176-179-
dc.identifier.urihttp://hdl.handle.net/10722/213173-
dc.description.abstractThe treatment of Non-Hodgkin's lymphoma (NHL) was revolutionized by the approval of rituximab in 1997. Rituximab is a CD20-directed monoclonal antibody (mAb). Despite the great success of rituximab in the treatment of B-cell NHL, the urgent need is to enhance the efficacy due to the markedly variable patient responses. Hence elucidating the molecular mechanisms of rituximab's anti-cancer effect is of great significance. In the past decade the atomic force microscopy (AFM) has proven to be a powerful tool for characterizing the morphological properties and measuring the physiological interaction forces of single cells and single molecules under native conditions. In this work, the AFM single-molecule force spectroscopy(SMFS) was applied to quantitatively measure the CD20-rituximab binding force on Burkitt's lymphoma patient bone marrow cells. The experimental results will facilitate further investigation of the molecular mechanisms of rituximab's anticancer effect. © 2010 IEEE.-
dc.languageeng-
dc.relation.ispartof2010 IEEE International Conference on Nano/Molecular Medicine and Engineering, IEEE NANOMED 2010-
dc.titleMeasuring the molecular force of Burkitt's lymphoma patient cells using AFM-
dc.typeConference_Paper-
dc.description.natureLink_to_subscribed_fulltext-
dc.identifier.doi10.1109/NANOMED.2010.5749829-
dc.identifier.scopuseid_2-s2.0-79956054567-
dc.identifier.spage176-
dc.identifier.epage179-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats